Tarek Sibai1, Elise F Morgan, Thomas A Einhorn. 1. Department of Orthopaedic Surgery, Boston University Medical Center, 720 Harrison Avenue, Suite 808, Boston, MA 02118, USA.
Abstract
BACKGROUND: The definition of bone quality is evolving particularly from the perspective of anabolic agents that can enhance not only bone mineral density but also bone microarchitecture, composition, morphology, amount of microdamage, and remodeling dynamics. QUESTIONS/PURPOSES: This review summarizes the molecular pathways and physiologic effects of current and potential anabolic drugs. METHODS: From a MEDLINE search (1996-2010), articles were identified by the search terms "bone quality" (1851 articles), "anabolic agent" (5044 articles), "PTH or parathyroid hormone" (32,229 articles), "strontium" or "strontium ranelate" (283 articles), "prostaglandin" (77,539 articles), and "statin" or "statins" (14,233 articles). The search strategy included combining each with the phrase "bone quality." Another more limited search aimed at finding more novel potential agents. RESULTS: Parathyroid hormone is the only US Food and Drug Administration-approved bone anabolic agent in the United States and has been the most extensively studied in in vitro animal and human trials. Strontium ranelate is approved in Europe but has not undergone Food and Drug Administration trials in the United States. All the studies on prostaglandin agonists have used in vivo animal models and there are no human trials examining prostaglandin agonist effects. The advantages of statins include the long-established advantages and safety profile, but they are limited by their bioavailability in bone. Other potential pathways include proline-rich tyrosine kinase 2 (PYK2) and sclerostin (SOST) inhibition, among others. CONCLUSIONS: The ongoing research to enhance the anabolic potential of current agents, identify new agents, and develop better delivery systems will greatly enhance the management of bone quality-related injuries and diseases in the future.
BACKGROUND: The definition of bone quality is evolving particularly from the perspective of anabolic agents that can enhance not only bone mineral density but also bone microarchitecture, composition, morphology, amount of microdamage, and remodeling dynamics. QUESTIONS/PURPOSES: This review summarizes the molecular pathways and physiologic effects of current and potential anabolic drugs. METHODS: From a MEDLINE search (1996-2010), articles were identified by the search terms "bone quality" (1851 articles), "anabolic agent" (5044 articles), "PTH or parathyroid hormone" (32,229 articles), "strontium" or "strontium ranelate" (283 articles), "prostaglandin" (77,539 articles), and "statin" or "statins" (14,233 articles). The search strategy included combining each with the phrase "bone quality." Another more limited search aimed at finding more novel potential agents. RESULTS:Parathyroid hormone is the only US Food and Drug Administration-approved bone anabolic agent in the United States and has been the most extensively studied in in vitro animal and human trials. Strontium ranelate is approved in Europe but has not undergone Food and Drug Administration trials in the United States. All the studies on prostaglandin agonists have used in vivo animal models and there are no human trials examining prostaglandin agonist effects. The advantages of statins include the long-established advantages and safety profile, but they are limited by their bioavailability in bone. Other potential pathways include proline-rich tyrosine kinase 2 (PYK2) and sclerostin (SOST) inhibition, among others. CONCLUSIONS: The ongoing research to enhance the anabolic potential of current agents, identify new agents, and develop better delivery systems will greatly enhance the management of bone quality-related injuries and diseases in the future.
Authors: M Machwate; S Harada; C T Leu; G Seedor; M Labelle; M Gallant; S Hutchins; N Lachance; N Sawyer; D Slipetz; K M Metters; S B Rodan; R Young; G A Rodan Journal: Mol Pharmacol Date: 2001-07 Impact factor: 4.436
Authors: Abraham Schneider; Linda M Kalikin; Ana C Mattos; Evan T Keller; Matthew J Allen; Kenneth J Pienta; Laurie K McCauley Journal: Endocrinology Date: 2005-01-06 Impact factor: 4.736
Authors: Kenneth E S Poole; Rutger L van Bezooijen; Nigel Loveridge; Herman Hamersma; Socrates E Papapoulos; Clemens W Löwik; Jonathan Reeve Journal: FASEB J Date: 2005-08-25 Impact factor: 5.191
Authors: R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak Journal: N Engl J Med Date: 2001-05-10 Impact factor: 91.245
Authors: David E Komatsu; Michael Hadjiargyrou; Sardar M Z Udin; Nicholas A Trasolini; Srinivas Pentyala Journal: Calcif Tissue Int Date: 2015-08-29 Impact factor: 4.333
Authors: Peeyush N Goel; Yasaman Moharrer; John H Hebb; Alexander J Egol; Gurpreet Kaur; Kurt D Hankenson; Jaimo Ahn; Jason W Ashley Journal: J Orthop Res Date: 2019-06-24 Impact factor: 3.494
Authors: M A Heffner; M J Anderson; G C Yeh; D C Genetos; B A Christiansen Journal: J Musculoskelet Neuronal Interact Date: 2014-03 Impact factor: 2.041